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Summary box
 ► Health economic evaluations and contextualised 
cost- effectiveness analyses (CEAs) are valuable 
tools for priority setting in emerging demographic, 
epidemiological and health system changes in low- 
income countries.
 ► This is the first published comprehensive compari-
son of contextualised CEAs for multiple health inter-
ventions targeting both non- communicable diseases 
(NCDs) and maternal, neonatal and child health.
 ► Scaling up maternal, neonatal and child health inter-
ventions, together with primary preventions of car-
diovascular diseases, gives higher expected health 
benefits and lower budget impacts than investments 
in other NCD interventions.
 ► The contextualised CEA method here is user- friendly 
and gives a clear visualisation of the opportunity cost 
when deciding on national healthcare investments.
ABSTRACT
Emerging demographic, epidemiological and health system 
changes in low- income countries require revisions of 
national essential health services packages in accordance 
with standard healthcare priority setting methods. Policy 
makers are in need of explicit and user- friendly methods 
to compare impact of multiple interventions. We provide 
experiences of country contextualisation of WHO- CHOICE 
methods and models to a country level. Results from three 
contextualised cost- effectiveness analyses (CEAs) are 
presented, and we discuss how this evidence can inform 
priority setting in Ethiopia. Existing models for a range of 
interventions in obstetric and neonatal care, psychiatric 
and neurological treatment and prevention and treatment 
of cardiovascular diseases are contextualised to the 
Ethiopian setting. CEAs are defined as contextualised if 
they include national analysts and use country- specific 
input for either costs, epidemiology, demography, baseline 
coverage or effects. Interventions (n=61) are ranked 
according to incremental cost- effectiveness rates (ICERs), 
and expected health outcomes (Disability Adjusted Life 
Years (DALYs) averted) and budget impacts are presented 
for each intervention. Dominated interventions (n=30) 
were excluded. A US$2.8 increase per capita in the annual 
health budget is needed in Ethiopia (currently at US$28 
per capita) for increasing coverage by 20%–75% for all 
the 22 interventions with positive net health benefits. 
This investment is expected to give a net benefit at 
around 0.5 million DALYs averted in return in total, with a 
willingness to pay threshold at US$2000 per DALY averted. 
In particular, three interventions, neonatal resuscitation, 
kangaroo mother care and antibiotics for newborn sepsis, 
stand out as best buys in an Ethiopian setting. Our method 
of contextualised CEAs provides important information for 
policy makers. Rank ordering of interventions by ICERs, 
together with presentations of expected budget impact and 
net health benefits, is a clear and policy friendly illustration 
of possible efficient stepwise pathways towards universal 
health coverage.
INTRODUCTION
Globally, most countries have committed 
themselves to move towards universal health 
coverage (UHC) which is a key subtarget of the 
Sustainable Development Goals for health.1–3 
UHC has been defined as all people receiving 
quality health services that meet their needs 
without being exposed to financial hardship 
in paying for the services.4 Given resource 
constraints, this does not entail all possible 
services, but a comprehensive range of essen-
tial services that is well aligned with other 
social goals.5 Competing priorities within the 
health sector and across other sectors necessi-
tates careful work in defining an optimal and 
feasible path to UHC.
Cost- effectiveness analysis (CEA) identi-
fies interventions that maximise population 
health, an important objective in resource 
constrained health systems.4 6 Health 
economic evaluations are now being used 
in several ongoing national benefit package 
revisions in low- income countries.7 Ranking 
interventions by cost- effectiveness can be 
used to explicitly identify the health services 
that deliver the highest health impact for the 
lowest cost. While recent academic debates 
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Table 1 Current coverage of 13 key maternal, child and 
neonatal health services in Ethiopia12




Neonatal resuscitation (institutional) 26
Kangaroo mother care 22
Newborn sepsis—Injectable antibiotics 26
Antibiotics for pPRoM 3
Management of pre- eclampsia and eclampsia 3
Antenatal corticosteroids for preterm labour 0
Induction of labour (beyond 41 weeks) 3
Safe abortion 37
Maternal sepsis case management 22
Active management of the 3rd stage of labour 23
Tetanus toxoid (pregnant women) 49




pPRoM, preterm premature rupture of membrane.
highlight the need to include concerns for fairness issues 
like financial risk protection8 and priority to worse off,5 9 
close attention to evidence about health maximisation 
and distribution is important in policy decisions.5
More health economists are needed in low- income 
countries. The majority of health economic evaluations 
are conducted in high- income countries. Regional CEAs 
may be the only available evidence in a low- income 
country. Often, important interventions lack evidence 
from health economic evaluations and fiscal analyses. 
Regional CEAs should be translated with caution to 
country levels, and preferably contextualised and para-
metrised to the respective country.10 Local demog-
raphy, epidemiology and health system may have large 
impact on expected costs and health effects. CEAs and 
results from one setting cannot easily be transferred to 
another.11 One way of overcoming this is to contextualise 
methods, data and analyses to ensure that models fit and 
reflect national health system objectives and constraints. 
Involvement of local health economists or other with 
similar skills is important in this work.
This paper presents a summary of results from three 
separate contextualised CEAs targeting maternal, 
newborn and child health (MNCH), mental and neuro-
logical conditions and cardiovascular diseases (CVD) 
from Ethiopia.12–14 In doing this, a total of 61 interven-
tions are rank ordered based on the incremental cost- 
effectiveness rates (ICERs). We discuss lessons learnt from 
the initial analytical processes and how this evidence can 
inform priority setting in Ethiopia.
ETHIOPIAN CONTEXT
Ethiopia is among the countries that shows a strong 
commitment to implement the UHC as part of aiming for 
the Sustainable Development Goals (SDG) for health.15 
With a GDP of US$ 772 per capita (2018),16 Ethiopia 
aspires to ‘…transition into a lower- middle income country by 
2025 and a middle- middle income country by 2035.’17 Aligned 
with that, the Ministry has conducted an ‘envisioning of 
the health sector’ towards UHC, where they identified 
good- performing and poor- performing lower middle- 
income countries in order to identify possible policy 
options that Ethiopia can learn from.17–19 Ethiopia devel-
oped an Essential Package of Health Services in 2005 that 
is currently under substantial revision.20 While Ethiopia 
has made significant progress in improving access to 
primary care over the past decades, the coverage remains 
low for most essential health services at a primary and 
specialised level (see table 1).21 Health economic evalu-
ations and fiscal space analyses of multiple interventions 
are needed with emerging non- communicable diseases 
and injuries (NCDI) and a still unfinished agenda for 
many of the paediatric, obstetric and infectious disease 
interventions.
Maternal, reproductive, neonatal, child and adolescent 
health is a cornerstone in the Health Sector Transfor-
mation Plan (2015–2020) in Ethiopia.17 However, such 
services are far from universally available, and further 
scale- up are likely to compete with a range of services 
for NCDI. Only 28% of all deliveries were conducted 
by a skilled person according to Ethiopia Demographic 
and Health Survey (2016).21 The launch of the National 
Mental Health Strategy in 2012 and the National Strategic 
Action Plan for Prevention and Control of NCDIs in 2014 
indicates a higher priority to mental and substance use 
disorders.22 23 A national commission on NCDI in Ethi-
opia recently launched an essential healthcare package 
for prioritised NCDI interventions.24 A majority of the 
mental health and neurological and CVD interventions 
are currently not publicly available, and the costs are 
therefore covered by the patients and their households 
in Ethiopia.25–27 Taking UHC as an overarching goal, 
Ethiopia envisages ambitious and progressive scale- up 
of a comprehensive range of services mainly through 
primary healthcare and the Health Extension Program.18 
So far, only a few CEAs are made based on contextualised 
data from Ethiopia.
SELECTING POLICY RELEVANT INTERVENTIONS
After consulting with the Ministry of Health officials 
in Ethiopia on what they found as the collection of the 
most policy relevant interventions, we assessed cost- 
effectiveness, targeting three broad disease categories 
separately: (1) treatment of newborn disorders (sepsis 
and other infections, respiratory distress, premature 
births, tetanus, still- births, birth asphyxia and compli-
cations during labour) and maternal disorders (sepsis, 
hypertensive disorders of pregnancy, intrapartum events, 
and unsafe abortion); (2) treatment of depression, 
schizophrenia, bipolar disorder and epilepsy and (3) 
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Figure 1 Contextualised cost- effectiveness of a complete 
set of interventions—ranking of 13 maternal and child 
health, 19 mental and neurological and 29 cardiovascular 
interventions by cost- effectiveness.
prevention and treatment of myocardial infarction and 
stroke. The range of interventions assessed was selected 
through an active participation of key policy makers in 
the Federal Ministry of Health (FMOH) in view of the 
envisaged policy direction: (i) relevance to the scale- up 
of primary healthcare and (b) emerging challenges from 
NCDIs such as CVD and mental health.
CALCULATING BEST BUYS
Population based models were used to estimate costs 
and effectiveness of the selected interventions. WHO- 
CHOICE regional CEA models were substantially revised 
with Ethiopian epidemiological, demographic, efficacy 
and cost data whenever possible. Details of the methods 
have been reported separately in the respective CEA 
papers.12–14 The currency year in each of the contextu-
alised CEAs are here inflation- adjusted to 2017 values 
to facilitate comparisons across all interventions. A null 
scenario with no coverage of services was used as baseline 
for each cardiovascular, mental and neurological inter-
vention to estimate ICERs. Therefore, the cheapest inter-
ventions presented here can actually be dominated since 
the null scenario of the mutually exclusive interventions 
are not presented in the tables. Current coverage was 
used to calculate ICERs of maternal, child and neonatal 
health services.12 Target coverages for all cardiovascular 
and maternal, child and neonatal health interventions 
were set to 20%, which was considered a realistic and not 
too ambitious coverage increase of these interventions in 
an Ethiopia setting. The existing National Mental Health 
Strategy in Ethiopia was used as a reference to set target 
coverage for treatment of depression (30%), bipolar 
disorder (50%), schizophrenia (75%) and epilepsy 
(75%).22
Figure 1 and table 2 show the results from the three 
contextualised CEAs. The ICERs for the interventions 
vary widely with an order of magnitude ranging by up to 
several hundred folds.
Figure 2 visualises the budget impact of investing in 
the 31 non- dominated interventions from table 1. A 
US$1 increase per capita in the annual Ethiopian health 
budget, currently at US$28,16 could allow inclusion of 
around half of these interventions into the health system.
Ochalek et al argue that information of ICERs are not 
sufficient for setting priorities between interventions 
since the size of potential health impacts are not spec-
ified with such rates.7 They argue that estimates of net 
DALYs averted best captures potential health impacts, 
and net health benefit of each intervention is presented 
at the bottom of figure 2. In our calculations of net 
health benefits, we set the Ethiopian willingness to pay 
threshold at US$2000 per DALY averted, acknowledging 
that this a rough and arbitrary threshold. More in- depth 
financial costing analysis is needed for better precision. 
Nine of the interventions (table 2) are expected to 
give negative or zero net health benefits in return with 
a US$2000 budget threshold. Priority to interventions 
with expected negative net health benefits, for example, 
primary percutaneous coronary intervention (PCI) for 
myocardial infarction, calcium supplementation during 
pregnancy and some of the mental health interventions, 
would thus cause more harm than good for population 
health in Ethiopia—if the willingness to pay threshold is 
less than US$2000 per DALY averted.
LESSONS LEARNT
To the best of our knowledge, this is the first comparison 
of comprehensive contextualised CEAs for health inter-
ventions in an Ethiopia setting. By using standardised 
and comparable methods and data inputs, we are able 
to produce a league table allowing reasonable compara-
bility across intervention categories. We describe CEAs 
as contextualised if they include national analysts and 
use country- specific input for either costs, epidemiology, 
demography, baseline coverage or effects. Several of 
the coauthors are Ethiopians and have experience with 
policy and planning, and they contributed substantially 
to the data collection and analysis. This was important for 
making the analyses policy relevant and locally relevant. 
In addition, this is important capacity building and a way 
to train people in Ethiopia in health economic methods. 
Defining, expanding and financing key services are argu-
ably the most important first steps in the process of trans-
lating results from CEAs to actual health policy. Below, 
we discuss our lessons learnt for each category of inter-
ventions in detail and point at the contribution these 
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Table 2 Contextualised cost- effectiveness of a complete set of interventions—ranking of 13 maternal and child health, 19 








Major depressive disorder Older antidepressants (TCA) 15 935 000 24 300 D –
Newer antidepressants (SSRI) 18 542 000 29 100 636 17
Psychotherapy 68 138 000 29 100 D –
Older antidepressants (TCA) and psychotherapy 69 632 000 34 100 D –
Newer antidepressants (SSRI) and psychotherapy 71 402 000 40 600 4621
Major depressive disorder Maintenance: Older antidepressants (TCA) and 
psychotherapy
62 081 000 58 900 1054 18
Maintenance: Newer antidepressants (SSRI) and 
psychotherapy
65 789 000 62 200 1135 19
Schizophrenia Typical antipsychotics 23 639 000 4900 D –
Atypical antipsychotics 23 635 000 6000 D –
Typical antipsychotics+psychosocial treatment 25 058 000 9000 D –
Atypical antipsychotics+psychosocial treatment 26 252 000 10 600 2465 24
Case id+management: Typical antipsychotics and 
psychosocial treatment
30 097 000 11 100 D –
Case id+management: Atypical antipsychotics and 
psychosocial treatment
31 290 000 11 600 5211 28
Bipolar affective disorder Older mood stabiliser (Lithium) 28 560 000 17 600 1627 22
Older mood stabiliser (Lithium) and psychosocial 
treatment
33 045 000 19 300 2518 25
Newer mood stabiliser (Valproate) 31 913 000 18 600 D –
Newer mood stabiliser (Valproate) and psychosocial 
treatment
36 418 000 20 500 2819 26
Epilepsy Older antiepileptic treatment (Phenobarbital) 30 874 000 68 900 448 16
Newer antiepileptic treatment (Carbamazepine) 67 170 000 68 900 HIGH 31
Acute ischaemic heart 
disease
ACE inhibitor 3 082 000 300 D –
Beta- blocker 3 084 000 600 D –
ASA 3 087 000 1000 D –
Streptokinase 3 662 000 1200 D –
ASA+clopidogrel 3 094 000 1400 D –
ASA+streptokinase 3 692 000 2100 D –
ASA+streptokinase+ACE inhibitor+beta- blocker 3 790 000 2100 D –
ASA+streptokinase+ACE inhibitor 3 700 000 2400 1544 21
Primary PCI 10 755 000 2700 D –
ASA+clopidogrel+PCI 11 032 000 4000 4529 29
Post- acute IHD Statin 3 552 000 300 D –
Beta- blocker 3 281 000 500 D –
ACE inhibitor 3 306 000 500 D –
ASA+beta- blocker 3 337 000 700 D –
ASA+beta- blocker+statin 3 659 000 1000 D –
ASA+beta- blocker+statin+ACE inhibitor 3 736 000 1600 2400 23
Acute ischaemic stroke ASA 3 282 000 100 52 102 30
Post- acute stroke ACE inhibitor 3 730 000 900 D –
ASA 3 707 000 1000 D –
ASA+statin 4 414 000 2400 D –
ASA+statin+ACE inhibitor 4 518 000 3300 1376 20
Continued
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Primary prevention of CVD Individual cholesterol treatment((tot. chol.>6.2 mmol/L) 6 059 000 8800 D –
Individual cholesterol treatment (tot. chol. >5.7 mmol/L) 13 778 000 19 100 D –
Individual hypertension treatment (SBP>160 mm Hg) 9 510 000 98 900 D –
Combination drug treatment for absolute risk of 
CVD>35%
9 315 000 125 700 74 5
Individual hypertension treatment (SBP >140 mm Hg) 25 196 000 125 700 D –
Combination drug treatment for absolute risk of 
CVD>25%
12 753 000 128 000 D –
Combination drug treatment for absolute risk of 
CVD>15%
18 696 000 153 900 333 14
Combination drug treatment for absolute risk of CVD>5% 34 835 000 190 400 442 15
Neonatal disorders Neonatal resuscitation (institutional) 353 000 54 700 6 1
Neonatal disorders Kangaroo mother care 287 000 36 700 8 2
Neonatal disorders Newborn sepsis—Injectable antibiotics 906 000 52 100 17 3
Maternal/neonatal disorders Antibiotics for pPRoM 591 000 8500 69 4
Neonatal disorders Antenatal corticosteroids for preterm labour 837 000 8600 98 6
Maternal disorders Safe abortion 737 000 6800 108 7
Maternal/neonatal disorders Management of pre- eclampsia and eclampsia 519 000 4800 108 7
Neonatal disorders Induction of labour (beyond 41 weeks) 393 000 2600 152 9
Maternal/neonatal disorders Tetanus toxoid (pregnant women) 2 688 000 16 000 168 10
Maternal disorders Maternal sepsis case management 1 151 000 5200 220 11
Maternal/neonatal disorders Syphilis detection and treatment (pregnant women) 1 522 000 6800 224 12
Maternal/neonatal disorders Active management of the third stage of labour 1 617 000 6600 244 13
Maternal/neonatal disorders Calcium supplementation 4 949 000 1600 3081 27
*2018 US$.
ACE, angiotensin- converting enzyme; ASA, acetylsalisylic acid; CVD, cardiovascular disease; ICER, incremental cost- effectiveness rate; IHD, 
ischemic heart disease; PCI, percutaneous coronary intervention; pPRoM, preterm premature rupture of membrane; SBP, systolic blood pressure; 
SSRI, selective serotonin reuptake inhibitors; TCA, tricyclic antidepressants.
Table 2 Continued
contextualised CEAs may provide to policy makers as well 
as its challenges and limitations.
Lessons: maternal and child health
Almost all of the maternal and neonatal health interven-
tions have low ICERs. The total annual cost of increasing 
coverage of all maternal and neonatal interventions by 
20% is estimated to be around US$21 million (US$0.2 per 
capita), with an aggregated expected net health benefit 
of around 204 000 DALYs averted. These services are also 
stated as high priority services in Ethiopian policy docu-
ments. Yet, they have a low effective coverage levels in 
Ethiopia. In a recent Lancet publication, Ruducha et al 
show how child mortality has decreased substantially in 
Ethiopia, and now neonatal morality makes up 46% of 
the under-5- mortality.28 For most policy makers, it is well 
known that maternal and child care services are effec-
tive and efficient interventions, while neonatal inter-
ventions have received less attention. In Memirie et al’s 
study, we found that introducing neonatal resuscitation, 
kangaroo mother care and treatment of newborn sepsis 
with injectable antibiotics in neonatal intensive care units 
have the lowest ICERs. The ICERs for these interventions 
are between US$6 and US$17/DALY averted and the 
expected net health benefits are expected to be 143 700 
DALYs averted in total, at a 20% incremental overage 
level.12 In the latest demographic health survey from 
Ethiopia (2016), the neonatal mortality rate is 29 deaths 
per 1000 deliveries. However, only 30% of children<6 
months with fever seek care at a health facility and 28% 
of all births are delivered by a skilled obstetrician or 
midwife or other trained skilled health personnel. While 
maternal and child health interventions have been, and 
still are high priority in Ethiopia, most of the NCD inter-
ventions analysed here have higher ICERs. There is a 
risk that a priority to NCDI interventions can diminish 
the priority to maternal and neonatal interventions and 
reduce population health levels. Solberg et al are some of 
the many arguing that saving a newborn life has relatively 
less value than saving older children or adult lives.29 If 
less value is given to save newborn lives, it may be justi-
fiable to diverge from obstetric and neonatal interven-
tions. Contextualised CEAs provide evidence and can 
visualise such trade- offs explicitly in fair and deliberative 
decision- making processes.
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Figure 2 Cost- effectiveness (DALYs averted per $1000), bar heights and cumulative budget impact, bar width, of all 31 
interventions that are not dominated, ordered from the lowest (left) to highest (right) cost- effectiveness (numerical values, 
including net health benefits (with WTP threshold $2000/DALY averted), are shown at bottom).
Lessons: cardiovascular diseases
Of note is that most of the CVD interventions in figure 1 
and table 2 were not included in the 2005 essential 
health services package.30 Many of these are now consid-
ered for being included in the package as part of the 
current revision. Primary prevention of CVD has one of 
the lowest ICERs of all 61 interventions. In the contex-
tualised CEA by Tadesse et al, we found that primary 
prevention of CVD in primary healthcare, at a health 
centre and primary hospital level, with an absolute risk- 
based approach cost between US$74 and US$442 /DALY 
averted (or between 2.3 and 13.5 DALYs averted per 
US$1000 invested). ICERs, health benefits and budget 
impact vary by risk eligibility threshold. A high threshold 
policy, >35% 10- year risk of CVD, is estimated to give 13.5 
DALYs in return per US$1000 invested (US$74/DALY 
averted), avert 121 000 DALYs and cost US$9.3 million in 
total. A low risk policy, 5% 10- year risk of CVD, is esti-
mated to give 2.3 DALYs in return per US$1000 invested 
(US$442/DALY averted), avert 28 000 DALYs and cost 
US$34.8 million in total. The reason why ICERs increase 
with lower risk thresholds is that the number of CVD 
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events prevented per person taking antihypertensives 
and statins diminishes with lower eligibility risk thresh-
olds. Even if primary prevention has low ICERs, it is 
important to think carefully how this service is best inte-
grated into the health system during a scale- up. The most 
advanced treatment of myocardial infarction (PCI and 
clopidogrel) has an ICER at US$4529 per DALY averted 
(0.2 DALYs averted per US$1000 invested) and negative 
net health benefits (−2000 DALYs averted), at a 20% 
incremental coverage level and a budget threshold of 
US$2000/DALYs. Streptokinase is slightly less efficacious 
than PCI, but has a much lower ICER (US$1544/DALY 
averted or 0.6 DALYs averted per US$1000 invested) and 
a net benefit at around 500 DALYs averted in an Ethio-
pian setting.
The health system in Ethiopia has up to now given 
high priority to interventions targeting communicable 
(eg, HIV, Tb and malaria) and MNC conditions. Primary 
prevention of CVD, and treatment of other chronic condi-
tions, depends on long- term patient- centred healthcare, 
trained personnel and well- functioning referral systems.31 
Health- information systems, sustainable delivery of drugs 
and regulatory capacities to manage private actors is also 
important in the implementation of primary prevention 
into the health system in Ethiopia. These are key chal-
lenges that policy makers need to handle when deciding 
whether primary prevention should be scaled- up in a 
country where the majority of the population live in rural 
areas. If only the interventions for CVD with the lowest 
ICERs, within the CVD category, were scaled- up by 20% 
in Ethiopia (primary prevention of CVD for individuals 
with >35% risk of CVD; ASA, streptokinase and ACE- 
inhibitor for treatment of acute myocardial infarction; 
ASA, beta- blocker, statin and ACE- inhibitor as secondary 
prevention after myocardial infarction and ASA, statin 
and ACE- inhibitor as secondary prevention after stroke), 
total annual health benefit is expected to be 122 600 
DALYs averted and budget impact is estimated to be 
around US$21.3 million (US$0.20 per capita).
Lessons: mental health
The mental health interventions have the highest ICERs 
of the ones we considered, and these interventions 
are seen, with low and wide bars, in the right corner 
of figure 2. In the CEA by Strand et al,13 we found that 
treatment of depression with antidepressants (SSRI) cost 
US$636/DALY averted (1.6 DALYs averted per US$1000 
invested) and is expected to avert 19 900 DALYs in total. 
The combination 18 hours of psychotherapy and older 
antidepressants (TCA) for preventing relapse of depres-
sion, gives an ICER at US$1134/DALY averted (0.9 DALYs 
averted per US$1000 invested) and a net health benefit 
of 27 900 DALYs averted. Treatment of epilepsy with 
phenobarbital cost US$448/DALY averted (2.2 DALYs 
averted per US$1000 invested) and a net health benefit 
of 53 500 DALYs averted. Previously, we have applied a 
methodology of Extended Cost- Effectiveness Analysis 
to this CEA of mental and neurological healthcare in 
Ethiopia. Around 80% of the investments for scaling- up 
treatment and maintenance of depression was expected 
to be returned in the form of productivity gains.26 Treat-
ments of disorders such as schizophrenia and bipolar 
disorders have higher ICERs and lower expected health 
benefits, but prioritising such services could be justified 
by assigning higher priority to more severe diseases.5 
Whether it is acceptable to introduce interventions with 
high ICERs due to other fairness concerns like severity 
of disease are important for policymakers to discuss 
and decide on. If so, the cost- effectiveness threshold for 
less severe diseases must be lower. If only the most cost- 
effective interventions for each of the mental and neuro-
logical conditions were scaled- up by 30%–75% in Ethi-
opia (SSRI and psychotherapy for depression; lithium 
for bipolar disorder; risperidone for schizophrenia and 
phenobarbital for epilepsy), total annual cost is estimated 
to be around US$156 million (US$1.5 per capita) and 
the total health benefit expected to be 102 000 DALYs 
averted.
CONTEXTUALISATION PROCESSES: THRESHOLDS AND 
BUILDING HEALTH ECONOMIC CAPACITY
In Ethiopia, as in most other countries, there is a strong 
pressure to implement interventions which are not cost- 
effective. Such investments can level down rather than 
level up population health by displacing alternative 
health interventions. One example is dialysis treatment 
for end- stage kidney diseases. While the ICER of this 
intervention is far higher than the ICERs presented in 
our study, many African countries are now providing dial-
ysis treatment in an increasing scale.32 33
Following suggestions by Claxton, Woods and 
others,34 35 we believe previous cost- effectiveness thresh-
olds were not well- founded on empirical grounds and may 
not indicate the actual opportunity costs of decisions.36 
New interventions can only be financed within existing 
budget constraints. Cost- effectiveness thresholds there-
fore become important in healthcare priority setting. 
Beneficial interventions are at risk of being displaced if 
less cost- effective interventions are introduced into the 
healthcare system without additional funding. As a conse-
quence, less population health may be achieved if cost- 
effectiveness thresholds are too high. A cost- effectiveness 
threshold is not suggested here, but we use a threshold 
of US$2000 per DALYs averted in the net health benefit 
analysis as an example. Budget threshold decisions are 
up to policy makers to decide on. Such threshold discus-
sions are important in order to succeed with a gradual 
and realistic scale- up of high priority services in the years 
to come. By rank ordering all these 61 interventions 
according ICERs, and excluding dominated interven-
tions, and by presenting the expected net health bene-
fits and budget impact of these interventions, we hope 
to provide policymakers accessible evidence that can be 
used to assess willingness to pay for these essential health-
care services.
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In these analyses, suboptimal target coverage levels are 
used. Target coverages were set based on discussion with 
experts from the different national health programmes 
in Ethiopia and all policy makers preferred analyses 
based on what they saw as feasible and realistic target 
coverage levels. This deviates from the WHO- CHOICE 
recommendation to estimate cost per health gain if inter-
ventions are implemented at full scale. Since ICERs in 
the models were not sensitive to target coverage levels 
(multiple levels were tested), we decided to adhere to 
demands of policy makers of applying what they saw as 
feasible targets.
Although our analysis is not exhaustive of all possible 
health interventions, we have demonstrated the impor-
tance of generating policy relevant and contextual-
ised evidence. One way of facilitating systematised and 
explicit priority setting is to train policy makers in doing 
CEAs with contextualised data and visualisation of results. 
Long- term investments in training and close collabora-
tions have been crucial in the development of the three 
studies presented here. Now, the Ethiopian coauthors of 
these CEAs provide technical support in national policy 
priority setting processes and independently conduct 
local CEAs. In addition, they are key in establishing a 
new Addis Ababa Centre for Ethics and Priority Setting 
(ACEPS) that aim to train decision makers in neigh-
bouring African countries to conduct health economic 
evaluations and systematic priority setting.
CONCLUSION
A comprehensive ranking of interventions in league 
tables provides comparability across categories of inter-
ventions and gives a clear presentation of evidence and 
opportunity cost. In systematic priority setting, such 
evidence should be considered together with concerns 
for equity and financial risk protection. An annual US$2.8 
investment per capita in 22 interventions in Ethiopia can 
increase coverage by 20%–75% and around 0.5 million 
net DALYs averted is expected in return in total per 
year—with a willingness to pay threshold at US$2000 per 
DALY averted. Capacity building is an important element 
in resource- constrained settings, as the demand for 
health economic evaluations are immensely high.
Twitter Kjell Arne Johansson @KA_Johansson
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